{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(4)"],"submitter":["Phattraprayoon N"],"funding":["Chulabhorn Royal Academy"],"pubmed_abstract":["<h4>Objective</h4>To determine the effects of oral vitamin A supplementation on clinical outcomes in preterm infants.<h4>Design</h4>We conducted the meta-analysis by searching PubMed/Medline, Scopus, Embase, CINAHL, and the Cochrane Library databases from inception to 12 August 2021, including reference lists of retrieved articles. Only randomized controlled trials (RCTs) evaluating the effects of oral vitamin A on premature babies were included. We used a random-effects model to calculate risk ratios (RRs) and weighted mean differences (MDs) with 95% confidence intervals (CIs). We used the GRADE approach to grade evidence quality and assess how oral vitamin A supplementation affects clinical outcomes.<h4>Main outcomes measures</h4>The primary outcomes were respiratory outcomes, including the length of respiratory support, the need for oxygen at 36 weeks postmenstrual age (PMA), and moderate-to-severe bronchopulmonary dysplasia (BPD) at 36 weeks PMA. Secondary outcomes were hospitalization time, vitamin A status, mortality, other related outcomes, and potential adverse drug-related events.<h4>Results</h4>We included four RCTs, with 800 patients total. In all trials, oral vitamin A treatment was compared to a placebo. Oral vitamin A supplementation did not significantly affect mechanical ventilation duration (MD, -1.07 days; 95% CI, -2.98 to 0.83 days), oxygen requirement at 36 weeks PMA (RR, 0.65; 95% CI, 0.33 to 1.31), or moderate-to-severe BPD at 36 weeks PMA (RR, 0.53; 95% CI, 0.07 to 4.17). However, oral vitamin A supplementation yielded a slightly shorter noninvasive ventilation duration (MD, -0.96 days; 95% CI, -1.59 to -0.33 days).<h4>Conclusions</h4>Administering oral vitamin A to preterm newborns did not alter the mechanical ventilation duration, oxygen needed at 36 weeks PMA, moderate-to-severe BPD at 36 weeks PMA, death, or short-term benefits. However, oral vitamin A supplementation may slightly affect the duration of noninvasive respiratory support without adverse drug-related events."],"journal":["PloS one"],"pagination":["e0265876"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8979433"],"repository":["biostudies-literature"],"pubmed_title":["Oral vitamin A supplementation in preterm infants to improve health outcomes: A systematic review and meta-analysis."],"pmcid":["PMC8979433"],"pubmed_authors":["Phattraprayoon N","Susantitaphong P","Soonklang K","Ungtrakul T"],"additional_accession":[]},"is_claimable":false,"name":"Oral vitamin A supplementation in preterm infants to improve health outcomes: A systematic review and meta-analysis.","description":"<h4>Objective</h4>To determine the effects of oral vitamin A supplementation on clinical outcomes in preterm infants.<h4>Design</h4>We conducted the meta-analysis by searching PubMed/Medline, Scopus, Embase, CINAHL, and the Cochrane Library databases from inception to 12 August 2021, including reference lists of retrieved articles. Only randomized controlled trials (RCTs) evaluating the effects of oral vitamin A on premature babies were included. We used a random-effects model to calculate risk ratios (RRs) and weighted mean differences (MDs) with 95% confidence intervals (CIs). We used the GRADE approach to grade evidence quality and assess how oral vitamin A supplementation affects clinical outcomes.<h4>Main outcomes measures</h4>The primary outcomes were respiratory outcomes, including the length of respiratory support, the need for oxygen at 36 weeks postmenstrual age (PMA), and moderate-to-severe bronchopulmonary dysplasia (BPD) at 36 weeks PMA. Secondary outcomes were hospitalization time, vitamin A status, mortality, other related outcomes, and potential adverse drug-related events.<h4>Results</h4>We included four RCTs, with 800 patients total. In all trials, oral vitamin A treatment was compared to a placebo. Oral vitamin A supplementation did not significantly affect mechanical ventilation duration (MD, -1.07 days; 95% CI, -2.98 to 0.83 days), oxygen requirement at 36 weeks PMA (RR, 0.65; 95% CI, 0.33 to 1.31), or moderate-to-severe BPD at 36 weeks PMA (RR, 0.53; 95% CI, 0.07 to 4.17). However, oral vitamin A supplementation yielded a slightly shorter noninvasive ventilation duration (MD, -0.96 days; 95% CI, -1.59 to -0.33 days).<h4>Conclusions</h4>Administering oral vitamin A to preterm newborns did not alter the mechanical ventilation duration, oxygen needed at 36 weeks PMA, moderate-to-severe BPD at 36 weeks PMA, death, or short-term benefits. However, oral vitamin A supplementation may slightly affect the duration of noninvasive respiratory support without adverse drug-related events.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-26T15:12:03.709Z","creation":"2025-04-06T14:52:01.452Z"},"accession":"S-EPMC8979433","cross_references":{"pubmed":["35377893"],"doi":["10.1371/journal.pone.0265876"]}}